| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Picfeltarraenin IB targets acetylcholinesterase (AChE), the enzyme responsible for the breakdown of acetylcholine in the synaptic cleft. By inhibiting AChE, the compound increases acetylcholine levels, enhancing cholinergic neurotransmission. The compound is also a potential inhibitor of PI3K and EGFR, key signaling molecules involved in cell proliferation and survival. These multiple activities make Picfeltarraenin IB a compound of interest for research into infection, cancer, and inflammation. Both Picfeltarraenin IA and Picfeltarraenin IB show stronger AChE inhibition than tacrine, a well-known AChE inhibitor used in the treatment of Alzheimer's disease.
|
|---|---|
| ln Vitro |
In vitro, Picfeltarraenin IB has been shown to inhibit acetylcholinesterase activity with greater potency than tacrine. Its AChE inhibitory activity suggests potential for the treatment of conditions associated with cholinergic dysfunction, such as Alzheimer's disease. The compound's potential PI3K and EGFR inhibition indicates possible anticancer activity. However, specific in vitro activity data, including IC₅₀ values for AChE, PI3K, and EGFR inhibition, are not extensively documented in the public literature. The compound is typically evaluated in enzyme activity assays and cell-based models to characterize its inhibitory effects.
|
| ln Vivo |
In vivo, Picfeltarraenin IB has been studied for its therapeutic potential in infection, cancer, and inflammation. Its strong AChE inhibition suggests potential applications in neurodegenerative diseases. However, detailed in vivo efficacy data for Picfeltarraenin IB are limited in the public literature. Further studies are needed to confirm its therapeutic potential in animal models of infection, cancer, inflammatory diseases, and neurological disorders.
|
| Enzyme Assay |
For in vitro enzyme assays, Picfeltarraenin IB is evaluated for its ability to inhibit acetylcholinesterase (AChE) activity using the Ellman's assay. The enzyme is incubated with acetylthiocholine iodide as substrate in the presence of varying concentrations of the compound. The hydrolysis product, thiocholine, reacts with DTNB to produce a yellow chromophore measured at 412 nm. Inhibition is calculated by comparing the rate of hydrolysis in the presence and absence of the compound. For PI3K and EGFR inhibition, kinase assays are performed using purified enzymes and appropriate substrates, with phosphorylation measured by radioactive or fluorescence-based detection.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines or neuronal cell lines are cultured in appropriate media and treated with Picfeltarraenin IB at various concentrations. Cell viability is measured by MTT or CCK-8 assays. Apoptosis is assessed by Annexin V staining. For AChE inhibition studies, neuronal cells are treated with the compound, and acetylcholine levels or cholinergic signaling is assessed. For anticancer studies, the compound's effects on cell proliferation, migration, and invasion are evaluated. For anti-inflammatory studies, immune cells are stimulated with inflammatory stimuli in the presence of the compound, and cytokine production is measured.
|
| Animal Protocol |
For in vivo animal studies, Picfeltarraenin IB is typically administered orally or intraperitoneally. In models of cancer, tumor-bearing mice are treated with the compound, and tumor growth is monitored. In models of neurodegenerative diseases, the compound's effects on cognitive function and cholinergic signaling are evaluated. In models of inflammation, the compound is administered to animals with induced inflammatory conditions, and inflammatory markers and tissue damage are assessed. Pharmacokinetic and toxicological studies may also be performed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Picfeltarraenin IB are not extensively characterized in the literature. As a cucurbitacin glycoside with a molecular weight of 792.95, the compound is expected to have poor oral bioavailability due to its high molecular weight and hydrophilic sugar moieties. It is likely administered parenterally in research settings. The compound's metabolism, distribution, and excretion have not been studied in detail. Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Picfeltarraenin IB are limited. As a natural product, the compound may have a favorable safety profile based on the traditional use of Picria fel-terrae. However, comprehensive toxicological studies have not been published. Standard laboratory safety precautions should be observed when handling the compound. The compound is not intended for human use in research settings.
|
| References | |
| Additional Infomation |
According to reports, picfeltarracemin IB has been found in Picria felterrae, and relevant data are available.
Picfeltarraenin IB is a research compound with no clinical trial or regulatory approval status. It is a cucurbitacin glycoside isolated from Picria fel-terrae Lour. The compound is of interest for its strong AChE inhibitory activity, which is more potent than tacrine. It also has potential PI3K and EGFR inhibitory activities. The compound can be used to study infection, cancer, and inflammation. It is available as a primary reference standard with assigned absolute purity. It is commercially available from chemical suppliers for research purposes only. |
| Molecular Formula |
C42H64O14
|
|---|---|
| Molecular Weight |
792.9492
|
| Exact Mass |
792.429
|
| CAS # |
97230-46-1
|
| PubChem CID |
21635747
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
895.7±65.0 °C at 760 mmHg
|
| Flash Point |
264.0±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.607
|
| LogP |
5.14
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
56
|
| Complexity |
1630
|
| Defined Atom Stereocenter Count |
19
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@@H]3CC[C@@H]4C(=CC[C@@H]5[C@]4(C(=O)C[C@]6([C@]5(C[C@H]([C@@H]6[C@]7(C(=O)C=C(O7)C(C)C)C)O)C)C)C)C3(C)C)CO)O)O)O)O)O
|
| InChi Key |
YRQJYHITIWJZQN-PGJHNFKZSA-N
|
| InChi Code |
InChI=1S/C42H64O14/c1-18(2)23-14-26(45)42(9,56-23)35-22(44)15-39(6)25-12-10-20-21(41(25,8)27(46)16-40(35,39)7)11-13-28(38(20,4)5)54-37-34(32(50)30(48)24(17-43)53-37)55-36-33(51)31(49)29(47)19(3)52-36/h10,14,18-19,21-22,24-25,28-37,43-44,47-51H,11-13,15-17H2,1-9H3/t19-,21+,22+,24+,25-,28+,29-,30+,31+,32-,33+,34+,35-,36-,37-,39-,40+,41-,42+/m0/s1
|
| Chemical Name |
(2S)-2-[(3R,8S,9R,10R,13R,14S,16R,17R)-3-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-16-hydroxy-4,4,9,13,14-pentamethyl-11-oxo-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-5-propan-2-ylfuran-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~315.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2611 mL | 6.3056 mL | 12.6111 mL | |
| 5 mM | 0.2522 mL | 1.2611 mL | 2.5222 mL | |
| 10 mM | 0.1261 mL | 0.6306 mL | 1.2611 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
